enVVeno Medical Reports Third-Quarter 2026 Financial Results, Study on Track
The initial 10-patient stage of the U.S. pivotal study of enVVe’s non-surgical replacement venous valve is on track to begin before year-end. The company said $18.5 million in cash and investments is expected to fund operations into Q4 2027, including the planned study initiation.
Story updates
12:32:44 PM UTC
SquawkNews
enVVeno reported Q3 2026 net loss of $4.4M ($6.29/share) and cash/investments of $18.5M, with ~$3M quarterly burn. It expects to begin the initial 10-patient Part 1 of the FDA-IDE TAVVE pivotal study before year end and projects funding into Q4 2027.Material DetailsContext by AI AnalystThis is a la…